Nestle's Prospects To Lead OTC Acne Market Gel With Differin Approval
Executive Summary
Differin Gel, the first NDA approved OTC acne treatment, could make Nestle the runaway leader in the market. The Swiss firm's Nestle Skin Health business owns Differin maker Galderma and has a majority stake in a JV marketing Proactiv.
You may also be interested in...
Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop
While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.
Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop
While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.
Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop
While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.